Pfizer Corporation

Raqualia Pharma Inc.

Kana Taniguchi

Seiji Nukui

Yoshiyuki Okumura

Kazunari Nakao

Akiyoshi Kawai

Tomoki Kato

Yoshinobu Hashizume

Miyako Matsumizu

Naomi Ueno

Yoriko Miyake

Katsuhiro Shinjyo

Masato Shimojo

Naomi Uneo

Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

Use of EP4 receptor ligands in the treatment of IL-6 involved diseases

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl ; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5&#x2013;6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Growing community of inventors

Aichi-ken, Japan

Kana Taniguchi